@article{991a9c6733604d52a9f0fc9bc658b272,
title = "Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma",
keywords = "chemotherapy, pancreatic cancer, survival, PHASE-III TRIAL, OPEN-LABEL, CANCER, CHEMOTHERAPY, MULTICENTER, FOLFIRINOX, RESECTION, SURVIVAL, THERAPY, TRENDS",
author = "{de Jong}, E.J.M. and Q.P. Janssen and T.F.A. Simons and M.G. Besselink and B.A. Bonsing and S.A.W. Bouwense and S.M.E. Geurts and M.Y.V. Homs and {de Meijer}, V.E. and V.C.G. Tjan-Heijnen and {van Laarhoven}, H.W.M. and {Valkenburg-van Iersel}, L.B.J. and J.W. Wilmink and {van der Geest}, L.G. and B.G. Koerkamp and {de Vos-Geelen}, J. and {Dutch Pancreatic Canc Grp}",
year = "2022",
month = may,
day = "15",
doi = "10.1002/ijc.33916",
language = "English",
volume = "150",
pages = "1654--1663",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley",
number = "10",
}